Literature DB >> 10086942

Improvement of nebulised antibiotic delivery in cystic fibrosis.

D Wilson1, M Burniston, E Moya, A Parkin, S Smye, P Robinson, J Littlewood.   

Abstract

AIM: To investigate deposition patterns and to assess the delivery rate of two nebuliser systems in children with cystic fibrosis (CF).
METHODS: Thirty three children with CF on regular treatment with nebulised antibiotics had radioisotope scans performed using technetium-99m labelled aerosol antibiotic generated by a Ventstream nebuliser (median mass diameter (MMD), 3.3 microm; delivery rate, 0. 075 ml/min) under conditions similar to their routine home practice. The inhomogeneity of the images was scored on a 1-10 rating scale (a low score indicating even distribution of the antibiotic), and stomach deposition was measured as a percentage of overall deposition. Twenty patients had a repeat scan using an Optimist nebuliser (MMD, 1.8 microm; delivery rate, 0.02 ml/min).
RESULTS: The mean inhomogeneity scores were 5.4 in the Ventstream group and 3. 5 in the Optimist group. Mean stomach deposition was 17.3% in the 33 patients using the Ventstream nebuliser. There was an inverse relation between height and stomach deposition (r = 0.69). In the 20 patients who had both nebulisers, the mean percentages of stomach deposition for the Ventstream and Optimist nebulisers were 11.8% and 1.6%, respectively. The Ventstream nebuliser delivered antibiotic at an average 2.8 times faster rate than the Optimist nebuliser. IMPLICATIONS: A smaller particle size results in a more homogenous distribution of the antibiotic in the lungs with decreased stomach deposition. This should not be seen as a recommendation to use the Optimist nebuliser because more antibiotic was delivered to most parts of the lung with the Ventstream because of its increased delivery rate.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086942      PMCID: PMC1717907          DOI: 10.1136/adc.80.4.348

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  18 in total

1.  Radioaerosol assessment of lung improvement in cystic fibrosis patients treated for acute pulmonary exacerbations.

Authors:  B L Laube; D Y Chang; A N Blask; B J Rosenstein
Journal:  Chest       Date:  1992-05       Impact factor: 9.410

2.  Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  M E Hodson; A R Penketh; J C Batten
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

3.  Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment.

Authors:  N H Valerius; C Koch; N Høiby
Journal:  Lancet       Date:  1991-09-21       Impact factor: 79.321

Review 4.  Aerosol antibiotic treatment in cystic fibrosis.

Authors:  J M Littlewood; S W Smye; H Cunliffe
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

5.  Lung deposition of nebulised pentamidine in children.

Authors:  M J O'Doherty; S H Thomas; D Gibb; C J Page; C Harrington; C Duggan; T O Nunan; N T Bateman
Journal:  Thorax       Date:  1993-03       Impact factor: 9.139

6.  Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

Authors:  B W Ramsey; H L Dorkin; J D Eisenberg; R L Gibson; I R Harwood; R M Kravitz; D V Schidlow; R W Wilmott; S J Astley; M A McBurnie
Journal:  N Engl J Med       Date:  1993-06-17       Impact factor: 91.245

7.  Simplified assessment of fine aerosol distribution in human airways.

Authors:  B L Laube; J M Links; H N Wagner; P S Norman; D W Koller; N D LaFrance; G K Adams
Journal:  J Nucl Med       Date:  1988-06       Impact factor: 10.057

8.  Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers.

Authors:  S H Thomas; M J O'Doherty; A Graham; C J Page; P Blower; D M Geddes; T O Nunan
Journal:  Thorax       Date:  1991-10       Impact factor: 9.139

9.  Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern.

Authors:  S P Newman; G Woodman; S W Clarke
Journal:  Thorax       Date:  1988-04       Impact factor: 9.139

10.  Does 99Tcm human serum albumin alter the characteristics of nebulized pentamidine isethionate?

Authors:  M J O'Doherty; S Thomas; C Page; A R Clark; D Mitchell; E Heduan; T O Nunan; N T Bateman
Journal:  Nucl Med Commun       Date:  1989-07       Impact factor: 1.690

View more
  1 in total

1.  The use of an alternate side lying positioning strategy during inhalation therapy does not prolong nebulisation time in adults with Cystic Fibrosis: a randomised crossover trial.

Authors:  Ruth L Dentice; Mark R Elkins; Genevieve M Dwyer; Peter T P Bye
Journal:  BMC Pulm Med       Date:  2018-01-08       Impact factor: 3.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.